Decoding 7 Analyst Evaluations For Catalyst Pharmaceuticals
7 analysts have expressed a variety of opinions on Catalyst Pharmaceuticals (NASDAQ:CPRX) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 4 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 3 | 3 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $29.29, with a high estimate of $34.00 and a low estimate of $23.00. Surpassing the previous average price target of $28.00, the current average has increased by 4.61%.
Exploring Analyst Ratings: An In-Depth Overview
An in-depth analysis of recent analyst actions unveils how financial experts perceive Catalyst Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Leland Gershell | Oppenheimer | Maintains | Outperform | $29.00 | $29.00 |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $34.00 | - |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $34.00 | - |
| Samantha Semenkow | Citigroup | Announces | Buy | $27.00 | - |
| Jason Gerberry | B of A Securities | Announces | Buy | $23.00 | - |
| Charles Duncan | Cantor Fitzgerald | Raises | Overweight | $34.00 | $27.00 |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $24.00 | - |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Catalyst Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Catalyst Pharmaceuticals compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Catalyst Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Catalyst Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Catalyst Pharmaceuticals analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
Unraveling the Financial Story of Catalyst Pharmaceuticals
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3 months period, Catalyst Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 81.98% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Catalyst Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of 31.51%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Catalyst Pharmaceuticals's ROE stands out, surpassing industry averages. With an impressive ROE of 9.46%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Catalyst Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 7.89%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
The Significance of Analyst Ratings Explained
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.